Jump to content

AdCLD-CoV19

From Wikipedia, the free encyclopedia

AdCLD-CoV19
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration
Intramuscular
Identifiers
CAS Number

AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,[2][3] a company from South Korea.[4]

A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.[5] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.[6] Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.[7] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.[8]

References

[edit]
  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ Chan-Hyuk K (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.
  3. ^ Chan-hyuk K (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.
  4. ^ "Cellid Co Ltd, Company Profile and News". Bloomberg Markets.
  5. ^ Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov
  6. ^ Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.
  7. ^ Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, et al. (April 2022). "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines. 10 (5): 712. doi:10.3390/vaccines10050712. PMC 9147121. PMID 35632468.
  8. ^ Cellid Co (27 August 2022). "A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.